New combo slows advanced breast cancer progression
NCT ID NCT02767661
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a low-dose chemotherapy pill (capecitabine) to standard hormone therapy (aromatase inhibitor) helps women with a common type of advanced breast cancer live longer without the disease getting worse. The trial involved 263 women who had not received prior treatment for their metastatic cancer. The goal was to see if the combination works better than hormone therapy alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?